Icon has previously acquired a 70% stake in Beacon Bioscience. Beacon Bioscience was renamed Icon Medical Imaging in 2007.
Peter Gray, CEO of Icon, said: “Medical imaging is playing an ever-increasing role in the development of new drugs and treatments. Through technology innovation, astute business management and a team of highly-skilled industry experts, Icon Medical Imaging has become a leader in its field. We believe that now is the right time to complete the acquisition of the remaining stake in the business.”